The US FDA's approval of a generic version of Adapt Pharma Ltd.'s Narcan (naloxone hydrochloride) nasal spray may represent an advance in the opioid overdose treatment's availability, but public health advocates argue a simple labeling change may prove more effective.
Many community health programs, who distribute naloxone to opioid users, often on small budgets, say that the label for generic...






